ASH 2019

Intended for scientific audiences only.

BMS at ASH 2019 

The next frontier in research and development at the American Society of Hematology, December 7-10, 2019.

By combining efforts, Bristol Myers Squibb and Celgene are pioneering innovation within the hematology space and expanding our research efforts into new spaces, including CAR T, one of the next frontiers in cell therapy. Read more on how hematology research may impact the future of care.

Giovanni Caforio, Chairman and Chief Executive Officer, Bristol-Myers Squibb

There’s More to Do For Patients: Our Strong Presence at ASH

Samit Hirawat on 2019 ASH meeting

Samit, Hirawat, Bristol Myers Squibb’s chief medical officer overseeing the Global Drug Development organization, speaks from the ASH meeting in Orlando..

Is CAR T-Cell Therapy A Potential Next Step for Multiple Myeloma?
cancer research
The Goal to Fight Lymphoma with New Approaches
Redirecting Immune Cells to Fight Myeloma
JAK2 is not 'Just Another Kinase'
Growing Up with Beta-Thalassemia: Taking Charge of Your Care
What’s in Store for CAR T-Cell Therapy in Relapsed / Refractory Lymphoma?
Do Lymphoma Subtypes Make a Difference in Treatment Decisions?
Three Things to Know About Venous Thromboembolism and Cancer

Learning About Hematology

Bristol Myers Squibb remains focused on its efforts to educate and help others understand the complexities of hematology. Learn more about blood disorders here.